clinical trial · NCT02814916
Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA
AbbVie·phase3·completed·n = 199
Methicillin-Resistant Staphylococcus AureusBacterial InfectionsStaphylococcal Skin InfectionsDalbavancinVancomycinOxacillinFlucloxacillinCefadroxilClindamycin
brief summary
To determine the safety and descriptive efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections in children, aged birth to 17 years (inclusive), known or suspected to be caused by susceptible Gram-positive organisms, including methicillin-resistant strains of Staphylococcus aureus.
started
Mar 30, 2017
primary completion
Jan 1, 2024
completion
Jan 1, 2024
last updated
Sep 19, 2024
official title
A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol